References
- Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res. 2017;10:1178646917691938. DOI: 10.1177/1178646917691938
- Oxenkrug GF. Role of Kynurenine Pathway in Insulin Resistance: Toward Kynurenine Hypothesis of Insulin Resistance and Diabetes. In: Mittal S, editor. Targeting the Broadly Pathogenic Kynurenine Pathway. Cham: Springer International Publishing; 2015. p. 169-78. DOI: 10.1007/978-3-319-11870-3_13
- Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring). 2015;23(10):2066-74. DOI: 10.1002/oby.21199
- Marszalek-Grabska M, Walczak K, Gawel K, Wicha-Komsta K, Wnorowska S, Wnorowski A, et al. Kynurenine emerges from the shadows - Current knowledge on its fate and function. Pharmacology & Therapeutics. 2021;225:107845. DOI: 10.1016/j. pharmthera.2021.107845
- Wang W, Huang L, Jin JY, Jolly S, Zang Y, Wu H, et al. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. Cancer Res. 2018;78(3):809-16. DOI: 10.1158/0008-5472.CAN-17-2995
- Duncan BB, Castilhos CD, Bracco PA, Schmidt MI, Kang S, Im S, et al. Aryl-hydrocarbon receptor binding and the incidence of type 2 diabetes: the Brazilian Longitudinal Study of Adult Health (ELSABrasil). Environ Health. 2020;19(1):105. DOI: 10.1186/s12940-020-00658-y
- Diabetes-Care. Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes Care. 1998;21 Suppl 2:B1-167.
- Angueira AR, Ludvik AE, Reddy TE, Wicksteed B, Lowe WL, Jr., Layden BT. New Insights Into Gestational Glucose Metabolism: Lessons Learned From 21st Century Approaches. Diabetes. 2015;64(2):327-34. DOI: 10.2337/db14-0877
- López-Hernández Y, Herrera-Van Oostdam AS, Toro-Ortiz JC, López JA, Salgado-Bustamante M, Murgu M, et al. Urinary Metabolites Altered during the Third Trimester in Pregnancies Complicated by Gestational Diabetes Mellitus: Relationship with Potential Upcoming Metabolic Disorders. Int J Mol Sci. 2019;20(5). DOI: 10.3390/ijms20051186
- Broekhuizen M, Danser AHJ, Reiss IKM, Merkus D. The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target? Int J Environ Res Public Health. 2021;18(21). DOI: 10.3390/ijerph182111545
- Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophankynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1-14. DOI: 10.1111/j.1749-6632.2009.05356.x
- Khambule L, George JA. The Role of Inflammation in the Development of GDM and the Use of Markers of Inflammation in GDM Screening. Adv Exp Med Biol. 2019;1134:217-42. DOI: 10.1007/978-3-030-12668-1_12
- Kozieł K, Urbanska EM. Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target? Cells. 2023;12(3). DOI: 10.3390/cells12030460
- Shen H, Xu X, Bai Y, Wang X, Wu Y, Zhong J, et al. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases. European Journal of Medicinal Chemistry. 2023;251:115258. DOI: 10.1016/j.ejmech.2023.115258
- Kubacka J, Staniszewska M, Sadok I, Sypniewska G, Stefanska A. The Kynurenine Pathway in Obese Middle-Aged Women with Normoglycemia and Type 2 Diabetes. Metabolites. 2022;12(6). DOI: 10.3390/metabo12060492
- Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264. DOI: 10.1155/2014/289264
- Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q. Oren-gedokuto and its constituents with therapeutic potential in Alzheimer’s disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis. 2010;22(1):257-66. DOI: 10.3233/JAD-2010-100684
- Türkiye-Endokrinoloji-ve-Metabolizma-Derneği. DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU 2022. 2022. p. 227.
- Tong Q, Song J, Yang G, Fan L, Xiong W, Fang J. Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. 2018;32(4). DOI: 10.1002/bmc.4156
- Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-50. DOI: 10.1016/j.diabres.2014.04.006
- Oxenkrug GF. Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. Mol Neurobiol. 2015;52(2):805-10. DOI: 10.1007/s12035-015-9232-0
- Oxenkrug G. Insulin resistance and dysregulation of tryptophankynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Molecular neurobiology. 2013;48(2):294-301. DOI: 10.1007/s12035-013-8497-4
- Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther. 2005;7(6):R1254-62. DOI: 10.1186/ar1821
- Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship between pyridoxal 5’-phosphate and inflammation. Nutr Rev. 2013;71(4):239-44. DOI: 10.1111/nure.12014
- Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004;200(8):1051-62. DOI: 10.1084/jem.20040942
- Mondanelli G, Albini E, Pallotta MT, Volpi C, Chatenoud L, Kuhn C, et al. The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes. Front Immunol. 2017;8:428. DOI: 10.3389/fimmu.2017.00428
- Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes. 2002;51(2):356-65. DOI: 10.2337/diabetes.51.2.356
- Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med. 2009;206(11):2511-26. DOI: 10.1084/jem.20090134
- Piras C, Neri I, Pintus R, Noto A, Petrella E, Monari F, et al. First trimester metabolomics 1H-NMR study of the urinary profile predicts gestational diabetes mellitus development in obese women. J Matern Fetal Neonatal Med. 2022;35(25):8275-83. DOI: 10.1080/14767058.2021.1970133
- Yu E, Papandreou C, Ruiz-Canela M, Guasch-Ferre M, Clish CB, Dennis C, et al. Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case-Cohort Study. Clin Chem. 2018;64(8):1211-20. DOI: 10.1373/clinchem.2018.288720
- Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J. 2013;34(34):2689-96. DOI: 10.1093/eurheartj/eht264
- Rebnord EW, Strand E, Midttun Ø, Svingen GFT, Christensen MHE, Ueland PM, et al. The kynurenine:tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia. 2017;60(9):1712-21. DOI: 10.1007/s00125-017-4329-9
- Theofylaktopoulou D, Midttun Ø, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173(1):121-30. DOI: 10.1111/cei.12092
- Watts SW, Shaw S, Burnett R, Dorrance AM. Indoleamine 2,3-diooxygenase in periaortic fat: mechanisms of inhibition of contraction. Am J Physiol Heart Circ Physiol. 2011;301(4):H1236-47. DOI: 10.1152/ajpheart.00384.2011
- Scarpellini E, Tack J. Obesity and metabolic syndrome: an inflammatory condition. Dig Dis. 2012;30(2):148-53. DOI: 10.1159/000336664
- Oxenkrug G, van der Hart M, Roeser J, Summergrad P. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients. Integr Clin Med. 2017;1(1). DOI: 10.15761/ICM.1000105
- Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463-73. DOI: 10.1523/JNEUROSCI.21-19-07463.2001
- Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52(4):1319-28. DOI: 10.1111/j.1471-4159.1989.tb01881.x
- Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780-6. DOI: 10.2337/dc11-1790
- Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. Bmj. 2022;377:e067946. DOI: 10.1136/bmj-2021-067946
- Nilsen RM, Bjørke-Monsen A-L, Midttun O, Nygård O, Pedersen ER, Ulvik A, et al. Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia. Obstetrics and gynecology. 2012;119(6):1243-50. DOI: 10.1097/AOG.0b013e318255004e
- Noto Y, Okamoto H. Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic islets. Acta Diabetol Lat. 1978;15(5-6):273-82. DOI: 10.1007/BF02590750
- Bennink HJTC, Schreurs WHP, Bennink HJTC, Schreurs WHP. Improvement Of Oral Glucose Tolerance In Gestational Diabetes By Pyridoxine. The British Medical Journal. 1975;3(5974):13-5. DOI: 10.1136/bmj.3.5974.13
- Gillmer MD, Mazibuko D. Pyridoxine treatment of chemical diabetes in pregnancy. Am J Obstet Gynecol. 1979;133(5):499-502. DOI: 10.1016/0002-9378(79)90283-7
- Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. Febs j. 2012;279(8):1356-65. DOI: 10.1111/j.1742-4658.2012.08485.x